Novel B-Cell Lymphoma 6 (BCL6) PROTAC

Novel pan-Bcl-2 family inhibitor, upregulating the BH3-only protein Noxa, which inhibits Mcl-1, inducing autophagy through (ER) stress and disruption of the interaction of Beclin 1 with Bcl-2

Novel efficient Bcl-2 inhibitor, exhibiting high specificity and stabilizing effect toward G-quadruplexes

Novel potent and selective degrader of Bcl-2

Novel inhibitor of the KRS-67LR interaction

Novel butyrylcholinesterase inhibitor (BChEi) for the treatment of canine cognitive dysfunction

Memory Enhancer and Free Radical Scavenger

Novel FBXO7/PINK1 interaction antagonist, abrogating FBXO7 and PINK1 association, leading to increased cellular PINK1 concentrations and activities, and limiting mitochondrial damage

Novel potent inhibitor of IL-2 secretion, demonstrating potent immunomodulatory activity

Novel potent apoptotic inducer of human leukaemia cells by activation of the extrinsic pathway and the generation of reactive oxygen species

Novel inhibitor of SARS-CoV-2 main protease (MPro)

Potent inhibitor of LpxC

Novel potent TRPM8 antagonist (IC 50 1.25 ± 0.26 μM)

Novel inhibitor of prion replication

Selective inhibitor of type A monoamine oxidase with dopaminergic properties

Novel potent and selective acetyl-CoA carboxylase (ACC) inhibitor, blocking WNT3A lipidation, secretion, and signaling

Novel potent and selective acetyl-CoA carboxylase (ACC) inhibitor

Negaitve control for BAY-390

Novel allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model

Negative control for BAY-678, a potent and selective human neutrophil elastase (HNE) inhibitor

Negative control for BAY-549

Novel allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model

Control compound for BAY-598, a novel potent inhibitor of SMYD2

Negative control for BAY299

Novel potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC 50 of 3 nM)

Negative control for BAY-3153

Novel MNK1 inhibitor, targeting oncogenic protein expression and showing potent anti-tumor activity

Negative control for BAY-091

Novel glucagon receptor antagonist

Novel cell-permeable synthetic peptide inhibitor of Bax, blocking apoptosis